HU Group-backed Fujirebio, a provider of the field of high-quality IVD testing, agreed to acquire ADx NeuroSciences, an R&D driven company specialized in the development of neurodegenerative biomarkers, for $41m. “It is a unique opportunity for us to completely integrate the CDMO-based open platform strategy of Fujirebio in this way. Our partners will benefit from the synergies between our teams and the speed with which we can bring our antibodies and assays to the diagnostics industry and on various platforms, all under the high-quality mark of excellence for which Fujirebio has become well known," Koen Dewaele, ADx NeuroSciences CEO.